Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.

British journal of clinical pharmacology - 1 Dec 2008

Kim Jung-Ryul, Seo Hyo-Bum, Cho Joo-Youn, Kang Do-Hyung, Kim Yong Ku, Bahk Won-Myong, Yu Kyung-Sang, Shin Sang-Goo, Kwon Jun Soo, Jang In-Jin

Abstract excerpt

AIMS: The aims of this study were to develop a combined population pharmacokinetic model for both aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients and to identify to what extent the genetic polymorphisms of cytochrome P450 (CYP) enzymes contribute to the variability in pharmacokinetics (PK). METHODS: A population pharmacokinetic analysis was performed using NONMEM software...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Drug Monitoring

Share to Mental Disorders

Share to Metabolic Clearance Rate

Share to Piperazines

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 19032724
DOI: 10.1111/j.1365-2125.2008.03223.x
PMCID: PMC2675764

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.PMID 19032724Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.Semantic proximity Read ↗

Population pharmacokinetics of aripiprazole in healthy Korean subjects.Semantic proximity Read ↗

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole.Semantic proximity Read ↗

Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.Semantic proximity Read ↗

Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrationsSemantic proximity Read ↗

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders.Semantic proximity Read ↗

CYP1A2*F Polymorphism Contributes at Least Partially to the Variability of Plasma Levels of Dehydroaripiprazole, an Active Metabolite of Aripiprazole, in Schizophrenic Patients.Semantic proximity Read ↗

Effects of CYP1A2 Polymorphisms on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients with SchizophreniaSemantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.